AI-enhanced metabolic imaging: a non-invasive and precise IVF assessment tool

项目摘要 非侵入性、客观的胚胎存活力评估的发展仍然是一个未满足的要求。 需要IVF治疗。在这项工作中，Optiva Fertility旨在开发一种新的胚胎评估方法， 基于代谢成像，使用荧光寿命成像（FLIM）结合 人工智能（AI）技术。迄今为止，Optiva Fertility已经设计、测试和部署了 第一代代谢成像系统，并已开始临床工作。 将这项技术提高到为IVF患者提供显着益处的程度需要 一个多阶段的开发和验证过程，构成拟议工作的基础 在这份赠款中。根据观察性初步试验的结果，Optiva将设计一个大型 大规模、多中心观察性试验。本研究的目的是获得足够大的数据集 训练强大的人工智能模型来评估胚胎的生存能力。为了促成这次审判 设计和构建第二代代谢成像系统， 紧凑和集成的硬件设计、自动校准、升级的控制软件， 和增强的成像技术。预计该系统将与 最终的商业产品。成功完成这项工作将进一步了解 代谢在胚胎存活中所起的作用，以及使Optiva处于有利地位， 进行一项关键的干预性试验。

Project Summary The development of a non-invasive, objective embryo viability assessment remains an unmet need in IVF treatment. In this work, Optiva Fertility aims to develop a novel embryo assessment based on metabolic imaging using Fluorescence Lifetime Imaging (FLIM) in conjunction with artificial intelligence (AI) techniques. To date, Optiva Fertility has designed, tested, and deployed a first generation metabolic imaging system and has commenced clinical work. Bringing this technology to the point where it provides significant benefit to IVF patients requires a multi-stage development and verification process which forms the basis for the proposed work in this grant. Based on the results from an observational pilot trial, Optiva will design a large scale, multi-site observational trial. The purpose of this study is to obtain a dataset large enough to train robust AI models for assessing embryo viability. Facilitating this trial will require engineering and constructing a second generation metabolic imaging system featuring a more compact and integrated hardware design, automated calibration, upgraded controls software, and enhanced imaging technology. It is anticipated that this system will be very similar to the eventual commercial product. Successful completion of this work will further the understanding of the role metabolism plays in embryo viability, as well as leave Optiva well positioned to undertake a pivotal interventional trial.